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Abstract
Apart from their role in hemostasis and thrombosis, 
platelets are involved in many other biological processes such 
as wound healing and angiogenesis. Percutaneous coronary 
intervention is a highly thrombogenic procedure inducing 
platelets and monocytes activation through endothelial trauma 
and contact activation by intravascular devices. Platelet P2Y12 
receptor activation by adenosine diphosphate facilitates 
non-ADP agonist-mediated platelet aggregation, dense granule 
secretion, procoagulant activity, and the phosphorylation of 
several intraplatelet proteins, making it an ideal drug target. 
However, not all compounds that target the P2Y12 receptor 
have similar efficacy and safety profiles. Despite targeting the 
same receptor, the unique pharmacologic properties of each 
of these P2Y12 receptor-directed compounds can lead to very 
different clinical effects.
Introduction
Platelet aggregation exerts an important role in ischemic 
complications in patients submitted to percutaneous 
coronary intervention (PCI). Both the atherosclerotic 
plaque instability and factors related to the procedure itself 
(endothelial trauma) and contact of thrombogenic structures 
and the blood are responsible for this process exacerbation1. 
Despite thromboxane A2 and adenosine diphosphate (ADP) 
act sinergistically in platelet activation, ADP interaction with 
its receptors, specially P2 receptors, enhances and sustains 
this activation. For this reason, these receptors have been 
the main target of current antiplatelet drugs2.
Platelet adhesion, activation and aggregation
Platelets are non-nucleated fragments of megakaryocytes 
that circulate in the blood stream and have a flattened disk 
conformation when not activated. They participate in a 
number of biological processes, from fighting infectious agents 
to initiating tissue repair by activating angiogenesis. Thus, their 
functions go well beyond the participation in the coagulation 
cascade, and they play a key role in modulating the whole 
tissue repair process3.
In normal conditions, platelets are not activated by 
the endothelial surface. The endothelial monolayer acts 
as an antithrombotic surface, since it does not allow the 
interaction of platelets and sub endothelial proteins and 
produces prostacyclin I2 and nitric oxide, which are, both, 
platelet activation inhibitors. Endothelial cells also express 
the CD39 enzyme, which converts adenosine triphosphate 
(ATP) to ADP and ADP to adenosine monophosphate 
(AMP), avoiding platelet activation by ATP and ADP4.
In the presence of vascular injury or trauma, sub 
endothelial proteins, such as Von Willebrand factor and 
collagen, are exposed and platelet adhesion occurs with 
the objective of promoting tissue healing. The interaction 
between these proteins and platelets is mediated by a number 
of receptors at the platelet surface (GPIbα, GPVI α2β1), 
and platelet activation occurs concomitantly to adhesion. 
Multiple metabolic pathways are stimulated, leading to an 
increase in calcium intracellular concentration. This increase 
activates phospholipase A2 and actin-myosin ATPase, leading 
to thromboxane A2 formation and platelet conformational 
change, respectively. When activated, platelets release their 
granules (containing ADP, ATP, serotonin, calcium, fibrinogen, 
Von Willebrand factors, cytokines and pro-thrombotic 
factors), increasing their volume and reactivity. In order to 
form this aggregate, platelets interact through the binding of 
fibrinogen and glycoprotein IIb/IIIa receptor5.
Platelet deposition at the vessel wall, leucocyte 
recruitment and smooth muscle cell migration promote 
an alteration in the arterial structure, known as vascular 
remodeling. This remodeling, together with the chronic 
inflammatory state mediated by platelets, consists in a key 
step in atherosclerotic plaque formation, intimal hyperplasia 
and stent restenosis6.
ADP and P2 platelet receptors
Secreted by red blood cells, endothelial cells and released 
in platelet granules, ADP is an important mediator of the 
activation and platelet aggregation amplification. ADP 
interacts with the platelet surface through receptors of the 
P2 family, whose two subtypes can be differentiated by the 
intracellular activation pathway: P2X (binded to ion channels) 
and P2Y (coupled to G protein). There is currently a new 
classification based on the agonist type: P2X1, activated by 
ATP; P2Y1 and P2Y12, activated by ADP (Figure 1)
7.
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The P2X1 receptors are responsible for a transient 
conformational change in platelets, which is associated 
to the rapid calcium influx. Thus, though not capable 
of sustaining platelet aggregation, they contribute to 
collagen-induced activation4.
P2Y1 receptors can be found in multiple tissues, 
including the heart, blood vessels, smooth muscular cells, 
nervous tissues, testicles, prostate and ovaries. In response 
to ADP-mediated activation, calcium is mobilized from 
platelet storage, leading to conformational change and 
transient aggregation. This receptor has a key role in the 
beginning of ADP-induced activation, but, for the effective 
stabilization of platelet thrombus, the activation of other 
receptors is required4,5.
P2Y12 receptors, besides being found in platelets, are also 
present in the microglia, endothelial cells and smooth muscle 
cells. These receptors have a central role in the amplification of 
the aggregation induced by all platelet agonists, such as collagen, 
thrombin, thromboxane A2, adrenaline and serotonin. Despite 
that, the agonist with the highest affinity, as observed with P2Y1 
receptors, is ADP. The intracellular response to its activation 
is the inhibition of cAMP (cyclic adenosine monophosphate) 
production, vasodilator-stimulated phosphoprotein (VASP) 
dephosphorylation and GTPase Rap1B and phosphoinositide 
3-kinase (PI3-K) activation. The activation of both P2 receptors 
is important to ADP-induced aggregation, since the selective 
inhibition of one receptor leads to an important reduction in 
platelet aggregation8.
P2Y12 receptor inhibitors
Antiplatelet drugs are essential in the management 
of patients submitted to PCI. There are three groups 
of antiaggregation drugs with proven clinical efficacy: 
cyclooxygenase inhibitors (AAS), P2Y12 receptor inhibitors and 
glycoprotein IIb/IIIa antagonists9.
The P2Y12 receptor is the main target of oral inhibitory 
agents, since it is directly involved in the amplification of the 
platelet reactivity required for thrombus formation. There 
are three classes of P2Y12 receptors: thienopyridines, ATP 
analogues and ciclopentil-triazolo pyrimidines (Table 1).
Figure 1 - P2 platelet receptors.
Reprinted from Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F,Macaya C, Bass TA et al. Variability in individual responsiveness to clopidogrel: clinical implications, 
management, and future perspectives. J Am CollCardiol. 2007;49(14):1505-16, with permission of Elsevier.
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Table 1 - P2Y12 receptor inhibitors
Drug Route Action Dosing (bolus/maintenance) Peak effect Main studies
Clopidogrel Oral IrreversibleHepatic metabolization
600 mg
75 mg/d 3 h
CURE-PCI
CLARITY-PCI
Prasugrel Oral IrreversibleHepatic metabolization
60 mg
10 mg/d 30 min TRITON-TIMI 18
Cangrelor IV ReversibleDirect inhibition
30µ/Kg/min
4 µ/Kg/min 1 min CHAMPION - PLATFORM
Ticagrelor Oral ReversibleDirect inhibition
180 mg
90 mg 12/12 h 30 min PLATO
CURE-PCI (Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention)10; 
CLARITY‑PCI (Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST elevation myocardial infarction treated with fibrinolytics)11; 
TRITON-TIMI 18 (Prasugrel versus clopidogrel in patients with acute coronary syndromes)12; PLATO(Ticagrelor versus clopidogrel in patients with acute coronary 
syndromes)13; CHAMPION-PLATFORM  (Intravenous platelet blockade with cangrelor during PCI)14.
Thienopyridines
Clopidogrel
The first and the second generation of thienopyridines 
are represented by ticlopidine and clopidogrel, respectively. 
Ticlopidine’s utilization is limited by a greater incidence 
of hematologic adverse effects, such as neutropenia and 
agranulocytosis. Clopidogrel is a pro-drug that must be 
metabolized in a two-step process by cytochrome P450 (CP450) 
in the liver to an active metabolite, which will irreversibly bind 
to the P2Y12 receptors. The majority of the absorbed clopidogrel 
(85-90%) is hydrolyzed in inactive carboxylic acid and the 
remaining is rapidly metabolized by CP45015. The 75-mg 
clopidogrel dose starts acting after two hours, but three to 
seven days are needed to achieve maximum platelet inhibition. 
The time for achieving its peak action, however, can be 
reduced with the utilization of loading doses. With a 300 mg- 
or 600 mg loading dose, maximum inhibition is achieved in 
12 and 3 hours, respectively.
It is worth highlighting that these are mean population 
values which do not reflect the necessary individual aggregation 
degree, since a number of pharmacokinetics studies were 
performed in normal individuals without coronary artery disease 
(CAD) and no damage to organs responsible for drug excretion 
or metabolization. Doses higher than 600 mg did not lead to 
more antiaggregation, since these doses did not lead to an 
increase in the concentration of the active metabolite4.
Clopidogrel, despite showing efficacy, cannot be 
considered the ideal antiaggregant. Its main inconveniences 
are its great individual variability, due to metabolic 
differences, the irreversible inhibition of the receptors, 
increasing bleeding risk specially in patients submitted to 
surgical procedures, and its latency to achieving the peak of 
action (reducing its benefit to acute coronary syndrome (ASC) 
patients needing fast platelet activity inhibition16.
Approximately 30% of the patients taking conventional 
doses of clopidogrel develop resistance or low response to 
the drug. This percentage represents a clinically vulnerable 
population with a high risk of major cardiovascular events, 
including AMI, stent thrombosis and death17.Various factors 
influence this individual variability, including obesity, 
diabetes mellitus, ASC, age and mutations in the genes 
coding P450 cytochrome enzymes.
The patients that are homozygous for mutant alleles 
of CYP2C19 present a high risk of cardiovascular events, 
mainly stent thrombosis2.Due to this evidence, the FDA 
issued an alert recommending that the utilization of other 
antiaggregation agent or unusual doses of clopidogrel 
be considered for these patients, individualizing platelet 
antiaggreagation18.
Individualized therapy is common in clinical cardiology. 
Various drug classes are dosed according to the clinical or 
laboratory response of the patient, such as anti-hypertensive 
and anticoagulant drugs, respectively.
The utilization of laboratory exams that allow a 
more precise evaluation of the individual variability in 
antiaggregant response is thus necessary. Currently, two test 
groups are available for this purpose: genetic and platelet 
reactivity tests. Since the genotype is constant, its evaluation 
is not capable of adequately measuring the cumulative 
influence and the dynamics of the various factors that 
interfere in platelet reactivity; thus, despite still limited by 
technical factors, it is more appropriate to evaluate the final 
phenotype than the genotype.
Platelet aggregation evaluation
The gold standard for platelet function evaluation is light 
transmission aggregometry. Despite that, the standardization 
of this method is difficult, demanding approximately four 
hours for its performance and requiring specific training. 
Bedside tests, such as VerifyNow®, have been highlighted by 
their easy utilization, rapid results, and for the lack of sample 
preparation requirement19.
A number of studies employed the ROC curve for defining 
the ideal platelet reactivity value relative to the thrombotic 
risk (cardiovascular mortality, stent thrombosis and non-fatal 
AMI). The best match between sensitivity and specificity was 
obtained with 240 P2Y12 reaction units (PRU)
15. More recently, 
the ADAPT-DES study reported that a PRU > 208 and a 
platelet inhibition percentage equal or inferior to 11% were 
independently associated to stent thrombosis20.
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The clopidogrel dose guided by VerifyNow® was 
evaluated in the GRAVITAS study. Chronic CAD patients 
that had been submitted to stent angioplasty and were 
considered resistant to clopidogrel (PRU > 240) were 
randomized to a doubled dose (bolus plus maintenance) or 
standard dose of clopidogrel. Despite the smaller PRU levels 
seen in the patients taking the higher clopidogrel dose, no 
difference was observed regarding primary outcome (death, 
non-fatal AMI and non-fatal stroke)21. In the ARTIC study, 
the number of events was not reduced by using platelet 
aggregation guided therapy after drug-eluting stents in the 
chronic CAD patient population22.
However, the study ADAPT-DES showed that, in patients 
with CAS, it was possible to evaluate stent thrombosis risk 
using PRU value, confirming the importance of the clinical 
presentation type (acute/chronic) to antiaggregation intensity20.
Another method for evaluating platelet aggregation is 
quantifying VASP (vasodilator-stimulated phosphoprotein) 
using flux cytometry. VASP is an intracellular protein activated 
by the binding of agonists to P2Y12 receptors12. In basal 
conditions, this protein is not phosphorylated and is regulated 
by the cAMP pathway, which is activated by prostaglandin 
E1 action and inhibited by ADP via the P2Y12 receptors. 
VASP phosphorylation is associated to P2Y12 receptor 
inhibition and the non-phosphorylated form is associated to 
these receptors’ activation. This method, however, demands 
intense laboratory work and is expensive15.
The difficulty in simulating in vitro hemostasis is the main 
barrier for the utilization of these tests23. The limitations 
for the evaluation of the platelet-endothelium and 
platelet-leukocyte interactions as well as the utilization of 
thrombotic surfaces as potential aggregation activators cannot 
be ignored; besides that, the utilization of agonists separately 
and in fixed concentrations is not similar to the physiological 
process. Other relevant point is that measuring aggregation 
in one blood sample is different from quantifying activity 
in the specific site of the tissue damage. Thus, the agonist 
may bind to the receptor, but intracellular pathways may 
exist that contribute to different responses when measuring 
platelet reactivity.
Prasugrel
Prasugrel, a third-generation thienopyridine drug, 
is a pro-drug with pharmacokinetic profile similar to 
clopidogrel which needs one less step to be converted to 
its active metabolite. Its distinct chemical structure allows 
a smaller dependency from CP450 for its activation. Its 
pharmacokinetics is more stable than clopidogrel since it 
is not influenced by CP450 mutations, resulting in a faster 
onset of action, and peak aggregation after 30 minutes16.
In the randomized study TRITON-TIMMI 38, prasugrel, 
when compared to clopidogrel, showed greater efficacy in 
significantly reducing IAM rates (7.4% vs 9.4%) and stent 
thrombosis (2.4% vs 1.1%) in ACS patients; however, patients 
treated with prasugrel presented higher bleeding rates 
(2.4% vs 1.8%) and the mortality rates were not significantly 
different. The subgroup analysis did not recommend its use 
by patients with past history of stroke/transient ischemic 
attack (TIA), individuals older than 75 years old or weighing 
less than 60 kg, due to increased bleeding risk. The patients 
with past history of stroke/TIA presented net damage with the 
utilization of prasugrel12. The drug was not able to reproduce 
the benefit seen with clopidogrel in patients with stable CAD 
or ACS without ST elevation treated conservatively24,25.
Despite prasugrel being considered more potent than 
clopidogrel, in vivo and in vitro studies showed that their active 
metabolites have equivalent potencies. Thus, its clinical benefit 
can be better explained by its better pro-drug conversion 
into active compounds than clopidogrel. Consequently, most 
patients treated with this drug tend to have faster inhibition 
of platelet aggregation16.
Cangrelor
ATP analogues are represented by cangrelor. This drug 
is a potent reversible inhibitor of P2Y12 receptors that does 
not need to be metabolized in order to act and is given only 
intravenously. Since it is an active metabolite, its peak of 
action is achieved in 2 to 30 minutes when given as a bolus 
or not, respectively. Its plasma half-life is six minutes, leading 
to a return to basal platelet aggregation one to two hours after 
finishing infusion. The studies that compared cangrelor and 
clopidogrel, however, were not able to show clinical difference 
between these drugs14,26.
The BRIDGE study compared cangrelor to placebo 
in patients who discontinued the thienopyridine due to 
upcoming surgical bypass. Cangrelor was able to maintain 
antiaggregation until the intervention without, however, 
increasing bleeding rates during surgery. Cangrelor 
utilization as a bridge to patients subject to high thrombotic 
risk that need to be submitted to surgical procedures seems 
to be promising27.
Ticagrelor
The most recent P2Y12 receptor inhibitor class is the 
ciclopentil-triazolo pyrimidines, represented by ticagrelor. 
Unlike the thienopyridines, ticagrelor does not need 
to be metabolized by the liver, interacts with platelet 
receptors reversibly and has faster onset and peak of 
action28. Action onset and peak are similar to clopidogrel 
in non-responding patients29.
Both efficacy and safety of ticagrelor were evaluated in the 
PLATO study, in which 18,624 ACS patients were randomized 
for receiving clopidogrel (75 mg/day, with a loading dose of 
300 to 600 mg) or ticagrelor (90 mg twice daily, with a 180 mg 
loading dose). The primary combined endpoint (mortality due 
to vascular cause, AMI or stroke) in 12 months was significantly 
smaller in the ticagrelor group (9.8% vs 11.7%). No significant 
difference was verified on major bleeding rates when the study’s 
major bleeding rate was used. However, when TIMI’s major 
bleeding criteria were used, the bleeding rate was higher in 
patients not submitted to myocardial bypass in the ticagrelor 
group (2.8% vs 2.2%; p = 0.03).The isolated analysis of AMI, 
vascular mortality and all-cause mortality rates showed a 
statistically significant rate in patients taking ticagrelor. In this 
study, the main adverse effects were dyspnea and bradycardia13.
280
Review Article
Falcão et al.
P2Y12 platelet receptors
Arq Bras Cardiol. 2013;101(3):277-282
One possible hypothesis for explaining the mortality 
reduction obtained with ticagrelor is that this drug has other 
effects besides antiplatelet action. Ticagrelor inhibits adenosine 
reuptake by red blood cells and is structurally related to 
adenosine, suggesting that the latter may be one of its 
metabolites. Adenosine has cytoprotective, anti-inflammatory, 
antifibrotic and cardioprotective properties, which could 
explain ticagrelor benefits. Adenosine can also justify the main 
adverse effects of this drug, such as dyspnea and ventricular 
pauses. More evidence is required, though, for confirming the 
direct association of ticagrelor and adenosine30,31.
Due to its short half-life, platelet reactivity returns to basal 
levels after 3 to 4 missing doses. This is important for patients 
requiring surgical intervention. However, bad drug adherence 
quickly exposes the patient to the risk of ischemic events.
Prasugrel vs. Ticagrelor
There are no studies comparing these drugs clinically; thus, 
care must be taken when extrapolating data from different 
papers. The study TRITON randomized the great majority of 
its patients (99%) with knowledge of their coronary anatomy, 
while PLATO, on the other side, randomized patients at the 
emergency room. The clopidogrel dose allowed in the two 
studies was also different. Approximately 50% of the patients in 
the PLATO study and 33% of the TRITON study patients were 
taking proton pump inhibitors. A final diagnosis of ACS with 
ST elevation was made in 37% of the patients in the PLATO 
study and 26% of the patients in the TRITON study. In PLATO, 
with the exception of patients submitted to thrombolysis, all 
therapeutic regimens were evaluated (interventionist, surgical 
and clinical), while in TRITON patients were randomized 
after intervention was indicated12,13. Thus, the two studies 
have different populations and designs, and it is not possible 
to compare the drugs.
Biondi-Zoccai et al32 evaluated both drugs in an indirect 
metanalysis and demonstrated the benefit of prasugrel 
regarding stent thrombosis and ticagrelor regarding major 
bleeding related to surgical bypass. No difference was 
observed regarding mortality, AMI or stroke32.
In a pharmacodynamic analysis of 44 ACS patients with 
high platelet reactivity after taking clopidogrel, Alexopoulos et 
al33 showed that ticagrelor provided lesser platelet inhibition 
than prasugrel (32.9 PRU vs. 101.3 PRU; p < 0.001).
Conclusions
Platelet antiaggregation is essential in the management of 
patients submitted to PCI. The risks of bleeding and thrombotic 
events must guide antiaggreagation therapy intensity. The more 
intense the antiaggregation, higher the peri and post-surgery 
bleeding risks. These risks must always be evaluated, since 
bleeding complications per se lead to a worse prognosis34. 
In the group of patients with chronic renal dysfunction, 
for example, dual platelet antiaggregation therapy greatly 
increases hemorrhagic events, reducing or even overriding 
PCI benefit on a medium term basis35. The bleeding risk can 
be evaluated by clinical prediction scores such as CRUSADE, 
but these scores do not have good prediction values, limiting 
proper evaluation of the hemorrhagic risk36.
In ACS patients, there is a high risk of thrombotic 
complications, an ideal scenario for early and intense platelet 
anti-aggregation; the same is not true for chronic CAD 
patients which, for this reason, are not to be exposed to high 
hemorrhagic risk.
Other option, not yet evaluated in randomized clinical 
studies, would be the utilization of more potentP2Y12 
receptor inhibitors (prasugrel or ticagrelor) in the acute 
phase of the coronary events, followed by a bridge with 
clopidogrel, aiming to reduce medium and long term 
bleeding risk. However, the duration of each therapy or 
whether this strategy would be really efficacious from a 
clinical point of view is still unknown and should not be 
recommended in daily clinical practice.
Antiplatelet selection must thus be carefully evaluated 
taking into account all adverse events, since its discontinuation 
imposes and increased risk of ischemic events to patients 
submitted to PCI. Accessing antiplatelet reactivity may allow 
anti-aggregation therapy individualization. However, tests for 
evaluating the response to platelet anti-aggregation drugs 
are still expensive, lack sensitivity and still require robust 
evidence showing clinical benefit.
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